Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (ALSE) Revenue
Annual & quarterly revenue history · segment & region breakdown
ALSE · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAlseres Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 10.74% year-over-year from $0.00B in FY2013.
Revenue trend
2013 – 1994 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2013-12-31 | $0.00B | -$0.00B | -10.74% |
| 2012-12-31 | $0.00B | +$0.00B | — |
| 2011-12-31 | $0.00B | +$0.00B | — |
| 2010-12-31 | $0.00B | +$0.00B | — |
| 2009-12-31 | $0.00B | +$0.00B | — |
| 2008-12-31 | $0.00B | +$0.00B | — |
| 2007-12-31 | $0.00B | +$0.00B | — |
| 2006-12-31 | $0.00B | +$0.00B | — |
| 2005-12-31 | $0.00B | +$0.00B | — |
| 2004-12-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Alseres Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Alseres Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Alseres Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ALSE revenue · 4 questionsALSE's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 10.74% year-over-year from $0.00B in FY2013.
▸ Source: FMP · Alseres Pharmaceuticals, Inc. SEC filings · GAAP · Alseres Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026